Processa Pharmaceuticals
PCSA
10 hedge funds and large institutions have $331K invested in Processa Pharmaceuticals in 2025 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 6 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 2
0.06% more ownership
Funds ownership: 0.14% → 0.2% (+0.06%)
3% less capital invested
Capital invested by funds: $342K → $331K (-$11K)
23% less funds holding
Funds holding: 13 → 10 (-3)
50% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
+$211K |
| 2 |
HF
HRT Financial
New York
|
+$138K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$88.3K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$84.2K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$22.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$202K |
| 2 |
VF
Virtu Financial
New York
|
-$8K |
| 3 |
TSS
Two Sigma Securities
New York
|
-$6.96K |
| 4 |
Citigroup
New York
|
-$6.53K |
| 5 |
SG
StoneX Group
New York
|
-$3.64K |
PCSA Hedge Fund Activity: Q4 2025 in Review
10 of the 8,252 institutional investors tracked by Wall St. Rank reported a position in Processa Pharmaceuticals (PCSA) for Q4 2025, worth a combined $331K — down 3.2% from $342K a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of PCSA and 3 opened new positions — a net loss of 3 holders — while 2 trimmed existing stakes and 4 added.
The largest buyer was Jane Street, opening a new position worth an estimated $211K. The largest seller was Stonepine Capital Management, cutting an estimated $202K.
- 10 institutional investors held Processa Pharmaceuticals (PCSA) as of Q4 2025, down from 13 in Q3 2025.
- Funds reported $331K of Processa Pharmaceuticals stock for Q4 2025, down 3.2% quarter-over-quarter.
- 3 funds opened new Processa Pharmaceuticals positions in Q4 2025 and 6 closed out, a net change of -3 holders.
- The largest Processa Pharmaceuticals buyer in Q4 2025 was Jane Street, an estimated $211K added.
- The largest Processa Pharmaceuticals seller in Q4 2025 was Stonepine Capital Management, an estimated $202K sold.
Based on aggregated 13F filings for Q4 2025.